02.16.11
Genzyme
4Q Revenues: $1.2 billion (+23%)
4Q Earnings: $471.9 million (earnings were $23.2 million 4Q10)
FY Revenues: $4.0 billion (+2%)
FY Earnings: $422.1 million (flat)
Comments: During the quarter, the company ceased fill/finish operations at its Allston facility for products sold in the U.S. According to the company, the recovery of Cerezyme supply is on track, and Fabrazyme supply is improving with allocations up 82% from the third to fourth quarter. Cerezyme sales in the quarter were up 111% to $222.0 million. Fabrazyme sales were up 6% to $61.6 million. Myozyme sales were up 39% to $127.5 million. For the year Cerezyme sales were down 9% and Fabrazyme were down 56%. Myozyme sales for the year were up 27%.
4Q Revenues: $1.2 billion (+23%)
4Q Earnings: $471.9 million (earnings were $23.2 million 4Q10)
FY Revenues: $4.0 billion (+2%)
FY Earnings: $422.1 million (flat)
Comments: During the quarter, the company ceased fill/finish operations at its Allston facility for products sold in the U.S. According to the company, the recovery of Cerezyme supply is on track, and Fabrazyme supply is improving with allocations up 82% from the third to fourth quarter. Cerezyme sales in the quarter were up 111% to $222.0 million. Fabrazyme sales were up 6% to $61.6 million. Myozyme sales were up 39% to $127.5 million. For the year Cerezyme sales were down 9% and Fabrazyme were down 56%. Myozyme sales for the year were up 27%.
